Theravance Biopharma to be Acquired by Zymeworks for $17.00 Cash Plus Contingent Value Right
TBPH sits 62% above its 52-week low of $10.578 on elevated volume (3.0× avg).
Summary
Theravance Biopharma has entered into a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, plus a Contingent Value Right (CVR) for future monetization of ampreloxetine. This acquisition follows a comprehensive strategic review and is expected to close in the second half of 2026.
Key Events · M&A and Partnerships · TBPH
-
Definitive Acquisition Agreement
Theravance Biopharma, Inc. has entered into a definitive Agreement and Plan of Merger with Zymeworks Inc. for an all-cash acquisition, plus a Contingent Value Right (CVR).
-
Merger Consideration
Shareholders will receive $17.00 per ordinary share in cash, representing an equity value of approximately $929 million. This represents a 22% premium to the stock price on March 3, 2026, and a 10% premium to the volume-weighted average price since that date.
-
Contingent Value Right (CVR)
Shareholders will also receive one CVR per share, entitling them to 80% of net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years. This includes a $50 million milestone payment upon the first commercial sale of ampreloxetine in a Major Market (US, UK, Spain, France, Germany, Italy) prior to the License Expiration Date.
-
Strategic Review Culmination
The transaction is the result of a comprehensive strategic review process conducted by the company's Strategic Review Committee and Board of Directors, aimed at maximizing shareholder value.
Analysis · TBPH · Life Sciences
This filing announces a definitive agreement for Theravance Biopharma to be acquired by Zymeworks. The deal offers shareholders immediate cash at a premium to recent trading prices, plus a Contingent Value Right (CVR) for potential future upside from the ampreloxetine asset. This marks the culmination of a strategic review process and fundamentally alters the company's future, making it a critical event for investors. The complex financing reorganization detailed in the exhibits is a key structural element of the acquisition.
At the time of this filing, TBPH was trading at $17.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $908.9M. The 52-week trading range was $10.58 to $21.03. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.